Print this page

STTR Award Boosts Research for UNM-based Therapeutic

Thursday, January 14 2021

With a newly awarded research grant, the GPER G-1 Development Group will continue to develop a novel therapeutic for the treatment of diabetes and obesity.  The technology comes out of the University of New Mexico Health Sciences center with research led by Eric Prossnitz, PhD, a professor in and chief of the Division of Molecular Medicine in the Department of Internal Medicine. The National Institutes of Health (NIH) Small Business Technology Transfer (STTR) grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Dr. Prossnitz said the funding presents an incredible opportunity to present an innovative approach to treating and preventing diabetes and obesity. GPER G-1 participated in the ASCEND 2020 Business Advising Cohort where executives received technology review and pitch preparation.

With a specialty in commercializing laboratory technologies, the New Mexico Start-Up Factory (NMSUF) launched GPER G-1 Development Group. Company officials said that the Phase I $300,000 award will fund continued testing and pre-clinical pharmacokinetic and toxicity studies.

GPER G-1 Development Group represents New Mexico-supported innovation at its finest – a biotech company making strides to bring forth the advancement of molecular medicine by developing discoveries made in the lab for applicable commercialization.  “I am proud that the results of our research are being advanced by a company that is working towards changing the way we treat and prevent diabetes and obesity,” said Prossnitz. “The ability to cultivate a promising technology discovered at the University of New Mexico and develop it through an STTR grant from the NIDDK is an incredible opportunity.”

Read the full article here!

Read 888 times Last modified on Tuesday, 31 August 2021 16:08